2. Academic Validation
  3. Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

  • Molecules. 2020 Dec 1;25(23):5672. doi: 10.3390/molecules25235672.
Bethany Almeida 1 2,  Okhil K Nag 2,  Katherine E Rogers 2 3,  James B Delehanty 2
Affiliations

Affiliations

  • 1 American Society for Engineering Education, Washington, DC 20036, USA.
  • 2 Center for Bio/Molecular Science and Engineering, Code 6900, U.S. Naval Research Laboratory, Washington, DC 20375, USA.
  • 3 Fischell Department of Bioengineering, 2330 Kim Engineering Building, University of Maryland, College Park, MD 20742, USA.
PMID: 33271886 DOI: 10.3390/molecules25235672
Abstract

In nanoparticle (NP)-mediated drug delivery, liposomes are the most widely used drug carrier, and the only NP system currently approved by the FDA for clinical use, owing to their advantageous physicochemical properties and excellent biocompatibility. Recent advances in Liposome technology have been focused on bioconjugation strategies to improve drug loading, targeting, and overall efficacy. In this review, we highlight recent literature reports (covering the last five years) focused on bioconjugation strategies for the enhancement of liposome-mediated drug delivery. These advances encompass the improvement of drug loading/incorporation and the specific targeting of liposomes to the site of interest/drug action. We conclude with a section highlighting the role of bioconjugation strategies in Liposome systems currently being evaluated for clinical use and a forward-looking discussion of the field of liposomal drug delivery.

Keywords

bioconjugation; drug delivery; liposome; targeting.

Figures